|
WO2021020885A1
|
|
Pharmaceutical composition for treating levodopa-induced dyskinesia or for suppressing progression thereof
|
|
KR20210014086A
|
|
Pharmaceutical compositions for treating or inhibiting the Levodopa-Induced Dyskinesia progression
|
|
WO2018174544A2
|
|
Antibody binding specifically to muc1 and use thereof
|
|
KR20180107005A
|
|
Antibody specifically binding to MUC1 and Use thereof
|
|
EP3528836A1
|
|
Methods of delivering a neuroprotective polypeptide to the central nervous system
|
|
WO2017082692A1
|
|
Multifunctional skin-permeating peptide having whitening, skin elasticity, wrinkle improvement, and wound healing activities
|
|
KR20170055919A
|
|
Multifunctional skin penetration peptide with whitening, skin elasticity, wrinkle improvement and wound healing ability
|
|
WO2017082690A1
|
|
Multifunctional skin-permeating peptide having whitening, skin elasticity, wrinkle improvement, and wound healing activities
|
|
KR20170055920A
|
|
Multifunctional skin penetration peptide with whitening, skin elasticity and wrinkle improvement ability
|
|
KR20170050632A
|
|
Dipeptide with activities of growth and activation of skin keratinocyte stem cell and use thereof
|
|
KR20170050633A
|
|
Tripeptide with activities of growth and activation of skin keratinocyte stem cell and use thereof
|
|
KR20160066284A
|
|
Novel transdermal delivery peptides and use thereof
|
|
KR20160066281A
|
|
Novel cell permeable peptide with high stability in plasma and use thereof
|
|
AU4477001A
|
|
Injectable sustained release pharmaceutical composition and processes for preparing the same
|
|
WO0172411A1
|
|
Reaction device for organic synthesis
|
|
AU7690200A
|
|
A chemical library preparation method from natural product
|
